Nahum M, Ratto G B, Motta G
Minerva Med. 1976 Apr 21;67(19):1263-75.
A new i.v., water-soluble aldosterone antagonist (potassium canrenoate) was employed for the first time in a series of patients operated for various forms of abdominal disease. The pharmacological and clinical effects of the drug were constantly reproduced and a marked anti-aldosterone activity was noted. The drug is felt to be specifically indicated in the management of secondary hyperaldosteronism typical of the immediate postoperative period.
一种新型静脉注射用的水溶性醛固酮拮抗剂（烯睾丙酸钾）首次应用于一系列因各种腹部疾病接受手术的患者。该药物的药理和临床效果不断得到重现，且观察到明显的抗醛固酮活性。该药物被认为特别适用于治疗术后早期典型的继发性醛固酮增多症。
